ENGLERINS: Englerin A was isolated based on the activity of the organic extract of the bark of Phyllanthus engleri Pax in the NCI 60 cell screen. The extract was identified in a retrospective bioinformatic analysis of testing data for 68,000 extracts, which sought to identify samples with the most selectivity against renal cancer cell lines. Bioassay guided fractionation of the extract led to isolation of the novel sesquiterpene diester, englerin A. Englerin A was isolated in high yield (1-4 g/kg dry wt.) from stem bark and root bark of the Tanzanian tree, Phyllanthus engleri Pax (Euphorbiaceae). Isolation required three purification steps. Other plant parts from the initial collection did not contain appreciable amounts of englerins and were devoid of anticancer activity. Three collections of bark collected from the original location in Iringa Province, Tanzania have all yielded similar amounts of englerin A, showing that natural collections are a viable source for preclinical development. The NCI currently possesses 6 g of pure englerin A which is available for development activities, isolated from Tanzanian bark. I recently reported a series of chlorinated analogues derived from englerin A, one of which has activity only 2.5-fold weaker than the natural product. Structure-activity studies have established several important points: a) Cell growth inhibition is not simply due to release of glycolate, a well-known but low-potency renal toxin, since a reverse ester analogue which cannot generate glycolate is active. b) The cinnamate moiety tolerates substantial variation without loss of activity. The cinnamate double bond plays a rigidifying role but its electronic contributions are not important. c) The isopropyl group plays an important role in activity, since its simplification to ethyl and methyl groups rapidly decreases potency. d) The cinnamate benzene ring is not required to be aromatic. Our current hypothesis is that the net effect of englerin A is to simultaneously starve the cells of glucose while creating an addiction to glucose. We believe that the selectivity depends on cells expressing both PKC-theta and HSF1 and/or being highly glucose dependent. Sensitivity to englerin A also correlates directly with sensitivity to 2-deoxyglucose, further highlighting the link between englerin A sensitivity, glucose dependence and PKC-theta activation. Englerin A was shown to be active in two different xenograft models. Pharmaceutical formulation and other preclinical development is ongoing. Collaborations with three synthetic chemistry groups have resulted in a number of active analogues which are being evaluated in tandem with the natural product. In addition, we have discovered that englerin A has excellent in vitro activity in a large panel of Ewing's sarcoma cell lines. SCHWEINFURTHINS: I isolated schweinfurthins A and B from the African plant Macaranga schweinfurthii Pax. The compounds displayed potent and selective activity against central nervous system, renal, and breast cancer cell lines in the NCI 60 cell assay, with GI50 values for four sensitive CNS tumor cell lines in the 10-25 nM range. The spectrum of anticancer activity did not match that of any currently used agent, indicating that these compounds might be acting at a previously unrecognized target or through a novel mechanism. Thus far, a total of 11 schweinfurthins have been isolated from nature. Synthetic strategies have been developed by the Wiemer lab (University of Iowa) to provide a reliable source of natural schweinfurthins and synthetic analogues for further biological testing. In the case of schweinfurthin F, total synthesis of the (R,R,R) and (S,S,S) enantiomers and comparisons of spectral data, optical rotations, and bioassay data with those reported for the natural product have resulted in assignment of the natural compounds as the (R,R,R) isomers. These synthetic efforts have continued, and most of the naturally occurring schweinfurthins have now been obtained by total synthesis. Investigations into the mechanism of action of schweinfurthins have yet to identify a proximate molecular target;however, in glioblastoma cell lines, it appears that a defective neurofibromatosis type 1 (NF1) pathway confers sensitivity. With a grant from the Children's Tumor Foundation, we are conducting a massive siRNA screen for potential targets at a CRO. My collaboration with the Lockett lab (FNLCR) has focused on the clear effect of natural schweinfurthins on the cellular actin cytoskeleton in sensitive cell lines. Development of pattern recognition algorithms for cellular images has enabled quantitation of changes in F-actin distribution with drug treatment. A synthetic analogue of schweinfurthin A has shown activity in an allograft model of peripheral nerve sheath tumor driven by an NF1 defect. Pharmaceutical development is ongoing. Testing of the analogue in an orthotopic model of MPNST is planned.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011470-02
Application #
8763549
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2013
Total Cost
$313,765
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Masaoka, Takashi; Zhao, Haiyan; Hirsch, Danielle R et al. (2016) Characterization of the C-Terminal Nuclease Domain of Herpes Simplex Virus pUL15 as a Target of Nucleotidyltransferase Inhibitors. Biochemistry 55:809-19
Fash, David M; Peer, Cody J; Li, Zhenwu et al. (2016) Synthesis of a stable and orally bioavailable englerin analogue. Bioorg Med Chem Lett 26:2641-4
López-Suárez, Laura; Riesgo, Lorena; Bravo, Fernando et al. (2016) Synthesis and Biological Evaluation of New (-)-Englerin Analogues. ChemMedChem 11:1003-7
Yeo, Dannel; Huynh, Nhi; Beutler, John A et al. (2016) Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model. J Invest Surg :1-7
Zhao, Haiyan; Lin, Zihan; Lynn, Anna Y et al. (2015) Two distinct modes of metal ion binding in the nuclease active site of a viral DNA-packaging terminase: insight into the two-metal-ion catalytic mechanism. Nucleic Acids Res 43:11003-16
Sourbier, Carole; Scroggins, Bradley T; Mannes, Philip Z et al. (2015) Tonantzitlolone cytotoxicity toward renal cancer cells is PKCθ- and HSF1-dependent. Oncotarget 6:29963-74
Ma, Jun; Pawar, Rahul S; Grundel, Erich et al. (2015) Sesquiterpenoid tropolone glycosides from Liriosma ovata. J Nat Prod 78:315-9
Huynh, Nhi; Beutler, John A; Shulkes, Arthur et al. (2015) Glaucarubinone inhibits colorectal cancer growth by suppression of hypoxia-inducible factor 1α and β-catenin via a p-21 activated kinase 1-dependent pathway. Biochim Biophys Acta 1853:157-65
Lockett, Stephen; Verma, Chrissie; Brafman, Alla et al. (2014) Quantitative analysis of F-actin redistribution in astrocytoma cells treated with candidate pharmaceuticals. Cytometry A 85:512-21
Hartung, Alyssa M; Beutler, John A; Navarro, Hernán A et al. (2014) Stilbenes as κ-selective, non-nitrogenous opioid receptor antagonists. J Nat Prod 77:311-9

Showing the most recent 10 out of 14 publications